Search clinical trials for: Imatinib Mesylate & Hydroxyurea

Total 2614 results

First Affiliated Hospital Bengbu Medical College

Unknown

Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer | Apatinib | Biomarker

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
Inhibikase Therapeutics, Inc.

Recruiting

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

CML

United States
Novartis Pharmaceuticals

Completed

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

Systemic Sclerosis, Scleroderma

United States, Germany, Italy, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

France, Italy, Germany, United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Therapy of Early Chronic Phase CML With Gleevec

Leukemia, Myeloid, Chronic-Phase

United States
Weill Medical College of Cornell University

Completed

Treatment of Polycythemia Vera With Gleevec

Polycythemia Vera

United States
National Cancer Institute (NCI)

Completed

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Synovial Sarcoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Hepatocellular Carcinoma Resectable
Tianjin Medical University Second Hospital

Unknown

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Small Cell Lung Cancer Extensive Stage

China
Peking University People's Hospital
Peking University Shougang Hospital; Peking University International Hospital

Withdrawn

Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial

Advanced Cancer | Soft Tissue Sarcoma Adult

China
University of Cincinnati
Novartis

Withdrawn

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myeloid Leukemia, Blast Crisis

United States
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Advanced Gastric Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

NSCLC

China
Fujian Medical University Union Hospital

Not yet recruiting

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST (PIRKER)

Gastrointestinal Stromal Tumor of Rectum

China
Novartis Pharmaceuticals

Completed

Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology...

Terminated

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States, Canada, Puerto Rico
Novartis Pharmaceuticals

Terminated

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Russian Federation
PETHEMA Foundation

Completed

Glivec in Ph Positive Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Cromosome Philadelphia Positive

Spain
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
University of Michigan Rogel Cancer Center
Novartis

Withdrawn

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Chronic Myeloid Leukemia

United States
American University of Beirut Medical Center

Recruiting

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Lebanon
The University of Hong Kong

Unknown

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

Chronic Myeloid Leukemia | Philadelphia Chromosome Positive CML

Hong Kong
Novartis Pharmaceuticals

Completed

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

All Indications for Glivec/Gleevec and Tasigna

United States
Novartis Pharmaceuticals

Completed

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

Japan
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Completed

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Wei Jiang
Wuzhou Red Cross Hospital; Laibin People's Hospital; Guangxi Naxishan Hospital; People's Hospital of Lingshan

Completed

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Novartis Pharmaceuticals

Completed

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Urogenital Neoplasms | Genital Neoplasms, Male | Prostatic Diseases | Antineoplastic Agents | Imatinib | Prostatic Neoplasm | Genital Diseases, Male | Neoplasms, Abdominal

Germany
King Faisal Specialist Hospital & Research Center

Completed

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Leukemia, Myeloid, Chronic
Centre Leon Berard
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance

Sarcoma | Gastro-intestinal Stromal Tumors (GIST)

France
Jan Beumer
Novartis Pharmaceuticals

Completed

Effect of Calcium on Gleevec Pharmacokinetics (PK) in Healthy Volunteers

Healthy

United States
National Cancer Institute (NCI)

Completed

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Poitiers University Hospital
Novartis; Ministry of Health, France

Terminated

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Chronic Myeloid Leukemia

France
Goethe University
German Federal Ministry of Education and Research; Deutsche Leukämie- & Lymphom-Hilfe

Recruiting

Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT (GMALL-EVOLVE)

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Germany
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
Lee, Stephanie
National Cancer Institute (NCI)

Completed

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Systemic Scleroderma | Graft Versus Host Disease

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Lung Cancer

United States
Versailles Hospital

Completed

A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML (OPTIMIMATINIB)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
M.D. Anderson Cancer Center

Terminated

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Uterine Cancer

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer (INV181)

Breast Cancer

Germany
Tianjin Medical University Cancer Institute and...

Unknown

Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Yan Li
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Breast Cancer
Chinese PLA General Hospital

Unknown

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Gastric Cancer

China
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

United States, Germany, United Kingdom, Italy, France, Switzerland
New York Medical College

Completed

SCT Plus Immune Therapy in Average Risk AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
University Hospital Center of Martinique

Completed

Comparison of Two Rhythm of Administration of Prostaglandin Gel for Induction of Labor (GELFREQ)

Labor Complication | Cervix

Martinique
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Glivec Phase II Pediatric Study

Cancer

France, United Kingdom, Netherlands
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China

Search clinical trials for: Imatinib Mesylate & Hydroxyurea

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations